For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
A systematic review and meta-analysis indicates that larger positive margins after surgical removal of the prostate are prognostic for disease recurrence.
Acceptance of active surveillance for low-risk prostate cancer hit a record high in 2021, although the US still lags internationally, new figures showed.
In pursuit of medical excellence and improved healthcare in Nigeria, The Redddington Hospital Group, Lagos has raised the bar in quality and affordable health care delivery service